Anti-fungal
NDC Package 53807-123-45
Package Information
Anti-fungal is shake well before useclean the affected area and dry thoroughlyapply a thin layer of the product over affected area twice daily (morning and night) or as directed by a doctorsupervise children in the use of this productthis product is not effective on the scalp or nails For athletes footuse daily for 4 weeks pay special attention to the spaces between the toeswear well-fitting, ventilated shoeschange shoes and socks at least once a dailyto prevent athlete's foot: clean and dry feet thoroughly, apply once or twice dailyFor jock itchuse daily for 2 weeks. Marketed by Rij Pharmaceutical Corporation, this product is identified by NDC 53807-123 and is authorized under FDA application part333C.
Identification & Billing
- RxCUI: 313422 - tolnaftate 1 % Topical Powder
- RxCUI: 313422 - tolnaftate 0.01 MG/MG Topical Powder
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 53807 - Rij Pharmaceutical Corporation
- 53807-123 - Anti-fungal
- 53807-123-45 - 45 g in 1 BOTTLE, DISPENSING
- 53807-123 - Anti-fungal
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 53807-123-45 identifies a specific commercial package of 45 g in 1 bottle, dispensing of Anti-fungal, labeled by Rij Pharmaceutical Corporation. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Rij Pharmaceutical Corporation on March 16, 1999. The current certification is valid through December 31, 2019.
How is this Rij Pharmaceutical Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 53807012345. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.